Results 51 to 60 of about 37,267 (288)

Fabrication of Organic/Inorganic Nanocomposites: From Traditional Synthesis to Additive Manufacturing

Advanced Materials, EarlyView.
It provides an overview of the synthesis of organic/inorganic nanocomposites, spanning from conventional methods to advanced 3D printing techniques. It summarizes key challenges in 3D‐printed nanocomposites and highlights emerging innovations, including 5D printing, AI‐assisted material design, nanoscale additive manufacturing, and sustainable closed ...
Liwen Zhang, Xumin Huang, Liwei Liu, Naufal Kabir Ahamed Nasar, Xinyan Gu, Thomas P. Davis, Xiaoyu (Rayne) Zheng, Lianzhou Wang, Ruirui Qiao   +8 more
wiley   +1 more source

Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.

PLoS ONE, 2022
Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management.
Maria Lourdes Posadas-Martinez, María Adela Aguirre, Erika Brulc, Maria Soledad Saez, Patricia Sorroche, Gerardo Machnicki, Mariana Fernandez, Elsa Mercedes Nucifora   +7 more
doaj   +1 more source

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

Advanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar, Weiwei Guo, Xin Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen   +7 more
wiley   +1 more source

Amyloid Forming Human Lysozyme Intermediates are Stabilized by Non‐Native Amide‐π Interactions

Advanced Science, EarlyView.
Mutational variants of human lysozyme cause fatal systemic amyloidosis by depositing kilograms of protein in the viscera of patients. Central to this process is a partially unfolded protein intermediate state that initiates aggregation into amyloid fibrils.
Minkoo Ahn, Julian O. Streit, Christopher A. Waudby, Tomasz Włodarski, Angelo Miguel Figueiredo, John Christodoulou, Janet R. Kumita   +6 more
wiley   +1 more source

Improving management of AL amyloidosis

Annals of the Academy of Medicine, Singapore, 2023
In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges.
Yuh Shan, Lee, Jeffrey, Huang
openaire   +2 more sources

Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery

Aggregate, EarlyView.
This review highlights recent progress in cell membrane‐coated lipid nanoparticles (CMC‐LNPs), focusing on their design, preparation methods, functional integration, and biomedical applications. It discusses various types of LNPs and coating strategies, characterization techniques, therapeutic functions, and applications.
Moataz B. Zewail, Guangze Yang, Yilong Fan, Yue Hui, Chun‐Xia Zhao, Yun Liu   +5 more
wiley   +1 more source

Peritoneal amyloidosis with myopathy in primary systemic (AL) amyloidosis [PDF]

BMJ Case Reports, 2017
We present an unusual case of primary systemic amyloidosis presenting with myopathy and peritoneal amyloid deposition. Peritoneal amyloid is a rare disease with few published cases.1 An 85-year-old man was referred to rheumatology with walking difficulties and elevation of serum creatine kinase (CK).
Ali Al-Adhami, Kate Steiner, Spencer Ellis   +2 more
openaire   +2 more sources

Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils

Aggregate, EarlyView.
This review addresses the gap between strong evidence for the involvement of amyloid fibrils in neurodegeneration and the failure of anti‐amyloid therapies, a phenomenon herein termed the “amyloid paradox.” To address this paradox, we provide a comprehensive summary of the current understanding of fibrils' pathogenic properties and mechanisms ...
Maksim I. Sulatsky, Olesya V. Stepanenko, Olga V. Stepanenko, Anna I. Sulatskaya   +3 more
wiley   +1 more source

Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets

Blood Science
Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis. This study aims to investigate the T-cell immune checkpoint expression patterns in systemic AL amyloidosis and its relationship with clinicobiological traits.
Jinghua Wang, Yujie Zhao, Pengjun Liao, Shuxin Huang, Youxue Huang, Shaohua Chen, Yangqiu Li, Liye Zhong   +7 more
doaj   +1 more source

An unusual case of chronic lymphocytic leukemia, multiple myeloma and cardiac amyloidosis

Journal of Community Hospital Internal Medicine Perspectives, 2017
Light chain amyloidosis has very rarely been reported in association with chronic lymphocytic leukemia (CLL). We reported on a 76-years-old female who presented with simultaneous kappa-restricted chronic lymphocytic leukemia (CLL) and a lambda-restricted
Dongyan Liu, Hakim T. Uqdah, Alisha D. Gordy   +2 more
doaj   +1 more source